Differential Binding of Inhibitors to Active and Inactive Cdk2 Provides Insights for Drug Design.
Kontopidis, G., Mcinnes, C., Pandalaneni, S.R., Mcnae, I., Gibson, D., Mezna, M., Thomas, M., Wood, G., Wang, S., Walkinshaw, M.D., Fischer, P.M.(2006) Chem Biol 13: 201
- PubMed: 16492568 
- DOI: 10.1016/j.chembiol.2005.11.011
- Primary Citation of Related Structures:  
2C5N, 2C5O, 2C5V, 2C5X, 2C5Y - PubMed Abstract: 
The cyclin-dependent kinases (CDKs) have been characterized in complex with a variety of inhibitors, but the majority of structures solved are in the inactive form. We have solved the structures of six inhibitors in both the monomeric CDK2 and binary CDK2/cyclinA complexes and demonstrate that significant differences in ligand binding occur depending on the activation state ...